Haemophilia
Haemophilia is a type of bleeding disorder in which the blood does not clot properly. Appropriate management aims to help people with haemophilia to live full, healthy and active lives, with the same opportunities as anyone else.
Together with Sanofi, we provide extended half-life recombinant replacement clotting factor treatments for haemophilia A and haemophilia B. Our ambition in haemophilia is to enable access to our treatments for everyone in our territory – Europe, most countries in the Middle East, North Africa and Russia – who has a need. Through our partnership with Sanofi and the wider haemophilia community, we are actively seeking to find solutions for the challenges facing all people with haemophilia.
Liberate Life - living a life beyond Haemophilia
In the summer of 2018, we undertook a large-scale, pan-European ethnographic study of the lives of 51 people living with haemophilia. These people, as well as their families, were monitored by researchers for 1-2 days, while 18 healthcare providers and five haemophilia experts were interviewed for further understanding. This in-depth research provided the main insights that inspired our vision for haemophilia: Liberate Life.
The Liberate Life vision reflects Sobi's long-term commitment to a life beyond haemophilia, to people with haemophilia being able to raise their ambitions from stability to possibility and live life to the fullest. It is also an inspirational call- to -action for involvement from the broader haemophilia community.
Read more at www.liberatelife.co.uk